IMBRIA PHARMACEUTICALS
Imbria Pharmaceuticals’ mission is to translate our understanding of cellular metabolism into innovative medicines that improve the lives of patients with limited or inadequate treatment options. The company was founded by doctors and launched by an all doctor executive team motivated by the promise of bringing new therapies to people in need. We are propelled by a deep scientific interest in cellular metabolism and the mitochondria, and are guided by both values and a code of business conduct built upon our commitment to always put the patients, families and communities we serve at the forefront of all that we do.
IMBRIA PHARMACEUTICALS
Social Links:
Industry:
Biotechnology Health Care Life Science Pharmaceutical
Founded:
2018-01-01
Address:
Boston, Massachusetts, United States
Country:
United States
Website Url:
http://www.imbria.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
80.95 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Apple Mobile Web Clips Icon Google Tag Manager GoDaddy DNS DigiCert SSL Microsoft Gravity Forms
Similar Organizations
Aura Biosciences
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.
Day One Biopharmaceuticals
Day One Biopharmaceuticals is a biotechnology company that focuses on developing new cancer therapies for patients of all ages.
Seismic Therapeutic
Seismic Therapeutic is a biotechnology company advancing machine learning for immunology drug development.
Current Employees Featured
Founder
Investors List
RA Capital Management
RA Capital Management investment in Seed Round - Imbria Pharmaceuticals
Sanofi Ventures
Sanofi Ventures investment in Seed Round - Imbria Pharmaceuticals
Key Employee Changes
| Date | New article |
|---|---|
| 2022-03-10 | Imbria Pharmaceuticals Strengthens Executive Leadership Team with New Appointments |
Official Site Inspections
http://www.imbria.com
- Host name: 104.47.160.14
- IP address: 104.47.160.14
- Location: Amsterdam Netherlands
- Latitude: 52.3534
- Longitude: 4.9087
- Timezone: Europe/Amsterdam
- Postal: 1091
More informations about "Imbria Pharmaceuticals"
About Us - Imbria
At Imbria, we are using our deep understanding of energy metabolism to develop novel therapies designed to substantially improve the lives of patients with life-altering cardiometabolic disorders. Our clinical stage pipeline is focused on …See details»
Imbria Pharmaceuticals - Crunchbase Company Profile & Funding
Imbria Pharmaceuticals’ mission is to translate our understanding of cellular metabolism into innovative medicines that improve the lives of patients with limited or inadequate treatment …See details»
Our Team - About Us - Imbria
Find Imbria's profiles of the leadership team and Board of directors, uniquely positioned to execute our mission.See details»
Imbria Pharmaceuticals - LinkedIn
Imbria is a privately held, clinical stage company developing novel therapies for patients with life-altering cardiometabolic disorders. Our clinical stage pipeline is focused on restoring or ...See details»
Imbria Pharmaceuticals - Overview, News & Similar companies
Mar 9, 2022 Who is Imbria Pharmaceuticals. Imbria Pharmaceuticals uses a deep understanding of energy metabolism to develop novel therapies designed to substantially improve the lives of …See details»
Imbria Pharmaceuticals - Craft
Imbria Pharmaceuticals is a company offering a pipeline of product candidates centered on two key areas in energy metabolism: heart disease and inborn errors of metabolism. It is focused …See details»
Imbria Pharmaceuticals - VentureRadar
Website: https://www.imbria.com/ Develops treatments focused on improving cellular energy production in conditions like cardiovascular disease and metabolic disorders ...See details»
Imbria Pharmaceuticals, Inc. - Drug pipelines, Patents ... - Patsnap
Imbria Pharmaceuticals plans to present full data from the phase 2 clinical trial at an upcoming event. ... The statistics for drugs in the Pipeline is the current organization and its subsidiaries …See details»
Imbria Pharmaceuticals - Contacts, Employees, Board Members, …
Imbria Pharmaceuticals is a biotechnology company with locations in San Diego, CA, and Boston, MA.See details»
Imbria Pharmaceuticals Appoints John Young to its Board of …
BOSTON, Mass., March 24, 2022 – Imbria Pharmaceuticals, Inc., a clinical stage, cardio-metabolic company developing novel therapies designed to enhance cellular energetics, ...See details»
Imbria Pharmaceuticals 2025 Company Profile: Valuation, Funding ...
Imbria Pharmaceuticals was founded in 2018. Where is Imbria Pharmaceuticals headquartered? Imbria Pharmaceuticals is headquartered in Boston, MA. What is the size of Imbria …See details»
Imbria Pharmaceuticals Overview | SignalHire Company Profile
Imbria Pharmaceuticals is a private company. The company currently specializes in the Biotechnology area. The Imbria Pharmaceuticals annual revenue is estimated at < 1M ...See details»
Imbria - Products, Competitors, Financials, Employees, …
Imbria's therapies target patients with non-obstructive hypertrophic cardiomyopathy, stable angina, and heart failure with preserved ejection fraction. Imbria was founded in 2018 and is …See details»
Our Values — About Us - Imbria
Patients first. We put patients first. Integrity. We do what’s right, not what’s easy. All in, all the time. We give everything we have, individually and as a team – patients are counting on us.See details»
Imbria Pharmaceuticals - Work in biotech
Imbria Pharmaceuticals is designing therapies to treat patients with life-altering cardiometabolic disorders by finding new treatments to enhance or restore how cells produce energy.Imbria’s …See details»
ACC 2025: Imbria’s ninerafaxstat data shows potential for ...
1 day ago In August 2022, Imbria Pharmaceuticals presented positive preliminary results from part one of the IMPROVE-DiCE trial at the European Society of Cardiology Congress. These …See details»
Pipeline - Imbria
Developing ninerafaxstat in three high value cardiometabolic indications. Phase 2 clinical trials have been completed in non-obstructive hypertrophic cardiomyopathy (nHCM), stable angina, …See details»
Imbria Pharmaceuticals Completes Enrollment in Phase 2 …
Jun 5, 2023 Imbria expects to report topline results from this trial in the fourth quarter of 2023. “Completing enrollment in the Phase 2 IMPROVE-HCM trial is an important step toward our …See details»
Media Center - Imbria
Imbria to Present Results from Phase 2 IMPROVE-ISCHEMIA Trial of Ninerafaxstat in Patients with Angina and Chronic Coronary Syndrome at the European Society of Cardiology Congress …See details»
Clinical Trials - Patients & Physicians - Imbria
We have completed clinical trials non-HCM and stable angina: IMPROVE-HCM Phase 2 Clinical Trial IMPROVE-HCM (NCT04826185) is a randomized, double-blind, placebo-controlled …See details»